« Back
Home /
Zoledronic Acid

Zoledronic Acid

Item no.	HY-13777-200mg
Manufacturer	MedChem Express
CASRN	118072-93-8
Amount	200 mg
Quantity options	100 mg 10 mM/1 mL 10 mM/1 mL 1 ea 200 mg 500 mg 50 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Breast Cancer Lymphatic System Cancer
Type	Inhibitors
Specific against	other
Purity	99.21
Citations	[1]Lianwei Wang, et al. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer. 2020; 20: 1059.\|[2]Hyung Joon Kim, et al. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis. Int J Mol Sci. 2019 Mar; 20(6): 1467.\|[3]Xiao-Lin Huang, et al. Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways. Int J Mol Med. 2019 Aug;44(2):582-592.\|[4]XIN HUANG, et al. Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro. Mol Med Rep. 2016 Jan; 13(1): 613-622.\|[5]Samantha Pozzi, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15;15(18):5829-39.\|[6]Shea GKH, et al. Oral Zoledronic acid bisphosphonate for the treatment of chronic low back pain with associated Modic changes: A pilot randomized controlled trial. J Orthop Res. 2022 Feb 23. ACS Nano. 2023 Jul 10.\|Appl Biochem Biotechnol. 2024 Mar 25.\|Bone. 2024 Aug 3:117222.\|Commun Biol. 2024 Nov 9;7(1):1476.\|Eur J Med Chem. 2024 Dec 5.\|Int Immunopharmacol. September 2022, 109030.\|J Dent Sci. 2024 May 4.\|JCI Insight. 2025 Jan 30:e184468.\|Med Oncol. 2023 Apr 10;40(5):141.\|Nat Commun. 2024 Mar 21;15(1):2529.\|Oxid Med Cell Longev. 2021 Mar 31.\|Cell Rep Methods. 2023 Oct 23;3(10):100599.\|Dis Markers. 2021 Oct 15;2021:5838582.\|Gut Microbes. 2023 Dec;15(2):2249143.
Smiles	OC(P(O)(O)=O)(P(O)(O)=O)CN1C=CN=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Zoledronate,CGP 42446,CGP42446A,ZOL 446
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; Autophagy; Bacterial
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, stored under nitrogen)
Molecular Weight	272.09
Product Description	Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects[1].
Manufacturer - Research Area	Cancer; Metabolic Disease
Solubility	H2O: 4.17 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Anti-infection; Apoptosis; Autophagy
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13777-200mg-safety-datasheet.pdf